ObsEva wraps up patients recruitiment for testing linzagolix, to treat certain heavy menstrual bleeding

ObsEva has completed recruiting patients for its Phase 3 clinical trial PRIMROSE 1 testing of oral gonadotropin releasing hormone (GnRH) receptor antagonist linzagolix for the treatment of heavy menstrual bleeding (HMB) associated with uterine fibroids (UF).

Read more